Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of August 2025, with the specific transaction date being August 4, 2025. The filing serves as a disclosure of share repurchases executed under a pre-existing non-discretionary agreement with Merrill Lynch International.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this specific document).
- Shares Purchased: 499,189 ordinary shares.
- Price Range: Lowest price paid was 1,383.50 GBp; highest price paid was 1,403.50 GBp.
- Average Price: Volume-weighted average price paid was 1,391.81 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Program Status: This purchase is part of an existing buyback programme initiated on June 4, 2025. Since the programme's inception, GSK has purchased 19,905,403 ordinary shares.
- Treasury Holdings: Following this transaction, GSK holds 238,039,786 ordinary shares in treasury.
- Shares in Issue: 4,077,348,699 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.84% of the total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the repurchase of 499,189 shares. The filing notes that the total number of voting rights remains 4,077,348,699, which serves as the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that any projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risks are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new specific guidance or outlook regarding future buyback volumes or financial performance is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (stated as 19,905,403).
- Confirm the current percentage of voting rights held in treasury (stated as 5.84%).
- Review the "Risk Factors" in the 2024 Form 20-F and Q2 2025 results for context on the company's broader financial health and risks.
- Check the remaining authorization or budget for the buyback programme, as this filing does not specify the total programme size or remaining capacity.